Reaction
Investigation Abnormal reporting signals
As of the last recalculation, Investigation Abnormal appears in 1,375 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is VENETOCLAX (PRR 26.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Venetoclax | 99 | 26.1 | 26.2 |
| Indomethacin | 19 | 22.0 | 22.0 |
| Tocilizumab | 146 | 21.6 | 21.6 |
| Azacitidine For | 20 | 16.9 | 16.9 |
| Leflunomide | 100 | 15.5 | 15.5 |
| Azacitidine | 24 | 12.4 | 12.5 |
| Ibrutinib | 61 | 11.9 | 11.9 |
| Hydroxychloroquine | 55 | 11.6 | 11.6 |
| Hydroxychloroquine Sulfate | 62 | 10.7 | 10.7 |
| Sulfasalazine | 53 | 10.6 | 10.6 |
| Desoximetasone | 13 | 10.4 | 10.4 |
| Thyroid, Porcine | 7 | 10.0 | 10.0 |
| Risankizumab-Rzaa | 45 | 8.6 | 8.6 |
| Ribociclib | 17 | 8.2 | 8.2 |
| Upadacitinib | 43 | 8.2 | 8.2 |
| Nilotinib | 15 | 7.8 | 7.8 |
| Tofacitinib | 75 | 6.5 | 6.5 |
| Acalabrutinib | 5 | 6.3 | 6.3 |
| Abatacept | 54 | 6.1 | 6.1 |
| Obinutuzumab | 6 | 5.5 | 5.5 |
| Golimumab | 30 | 5.4 | 5.4 |
| Pirfenidone | 14 | 5.2 | 5.2 |
| Atezolizumab | 11 | 4.3 | 4.3 |
| Glecaprevir And Pibrentasvir | 3 | 4.1 | 4.1 |